



Cancer Specific Exclusion Criteria for arm 1, 2

Breast Cancer Patients, invasive ductal carcinoma, stage I, II, III to receive standard of care neoadjuvant or adjuvant TC, ACT, ddACT, FEC, CMF, TCHP, TCH, or TH

Colon Cancer Patients, adenocarcinoma, stage II, III to receive standard of care neoadjuvant or adjuvant, FOLFOX or CapeOX; patients aged 70 or older receiving 5FU/leucovorin

Bladder Cancer Patients, infiltrating urothelial carcinoma, stage II,III, standard of neoadjuvant DDMVAC, Gemcitabine and Cisplatin, or CMV

Head and Neck Cancer Patients, nonsquamous or squamous invasive carcinoma, Stage III, IVA, IVB, standard of care treatment definitive high-dose cisplatin with RT, carboplatin/5FU/RT, or standard of care treatment post operative cisplatin, or docetaxol/cetuximab

Thoracic Cancer Patients, Stage IIA, IIB, IIIA, IIIB, nonsmall (nonsquamous, squamous) cell lung invasive carcinoma, standard of care definitive neoadjuvant or adjuvant chemo/RT or chemotherapy cisplatin or carboplatin based doublet therapy

Cancer Specific Exclusion Criteria for arm 1, 2

Colon: Any stage with use of only adjuvant 5FU/leucovorin for curative intent treatment.

Breast Cancer: Inflammatory breast cancer, Phyllodes tumor

Bladder Cancer: Any stage with use of carboplatin instead of cisplatin for curative intent, urachal tumors

Head and Neck Cancer: Unresectable malignancy without ability to have definitive chemo/RT, Nasopharyngeal Cancer undergoing induction/sequential systemic therapy ,or receiving carboplatin instead of cisplatin

Thoracic Cancer: Superior Sulcus Tumors